How to fund your biotech breakthrough
Are you a small biotech start-up looking for advice on funding options? This webinar will give an explanation of each funding stage, from government grants right through taxation schemes to VC funding and eventually listing. The webinar will be set up as a whole life story of a fictional company from start to listing, to give an example of how the funding landscape can be used to its full potential.
Join us to learn how and when you should be tapping into these funding opportunties.
John co-founded Calculus Capital with Susan McDonald in 1999, creating one of the UK’s most successful, independent private equity firms focused on investing in smaller, proven companies.
John has over 30 years’ experience in private equity, corporate finance, and operational management. During that time, he has invested in, advised on or negotiated more than 100 transactions and served on publicly quoted and private corporate boards.
Before co-founding Calculus Capital, John served as an Executive Director of European Corporate Finance for UBS for nine years where he advised on M&A, IPOs, restructurings and recapitalisations, strategic alliances and private equity. Prior to this, John was headhunted to be Head of the Mergers & Acquisitions Group of Philips and Drew, a 100 year old London based financial institution. At the start of his career, John qualified as a Chartered Accountant with Peat Marwick (subsequently KPMG), where he then went on to be recruited as a founder member of Deloitte’s newly established consultancy practice in the Gulf Region and then Corporate Finance practice in London.
John graduated from Oxford University with an MA (Hons) in Philosophy, Politics and Economics.
Michael is an Innovation Lead for the Biomedical Catalyst funding programme at Innovate UK, the UK’s innovation agency. The Biomedical Catalyst has provided over £125m grant funding to innovative healthcare SMEs since 2012.
Michael joined the Medicines & Healthcare products Regulatory Agency (MHRA) as Group Manager for the Medical Devices Safety & Surveillance Group and led a team of ~40 engineers and scientists whose primary focus was patient safety. There are >500,000 individual medical devices in the UK including in-vitro diagnostics, hip replacements, wheelchairs, pacemakers, contact lenses and certain stand-alone software packages. No medical device is without risk and the team helped monitor the safety of devices and sought to work collaboratively with manufacturers and stakeholders to ensure that when issues arose, they were dealt with appropriately and promptly. The team were also heavily involved in the development of standards, future regulation and pre-market clinical investigations of non-CE marked medical devices.
Oliver Sexton is an Investment Director at the UK Innovation & Science Seed Fund where he focuses on life science investments across the healthcare, renewable and clean tech spaces. Oliver is on the board of companies as diverse as Quethera developing therapeutics for eye disorders, Procarta developing novel anti-biotics and an observer for companies including Synthace, Nemesis BioSciences.
Prior to joining UKI2S , Oliver spent four years at Imperial Innovations and earlier in his career held commercial and partnering roles at Ark Therapeutics as well as managing a team of biotech buy-side analysts and worked at a pharma strategy consultancy.
Oliver has a BSc in Molecular Biology/Biotechnology and an MSc from Bristol University.
Responsible for sourcing and analysing potential investments, due diligence and deal closing activities. Previous Strategy Consulting and Private Banking experience with PWC and Itaú BBA Securities respectively. B.Sc. (Hons) in Economics from the University of Birmingham and M.Sc. in Economics and Strategy for Business from Imperial College London.